CD74 siRNA and shRNA Plasmids (h)

siRNA / RNAi /miRNA transfection Human Cells - HT-1376 CD74

Experiment
siRNA / RNAi /miRNA transfection Human Cells - HT-1376 CD74
Product
CD74 siRNA and shRNA Plasmids (h) from Santa Cruz Biotechnology
Manufacturer
Santa Cruz Biotechnology

Protocol tips

Upstream tips
Cells were seeded at 2×105 cells/well in 6-well plates (Corning Incorporated, Corning, NY, USA) and grown to 60% confluence on the day of transfection.
Protocol tips
The media was removed from the plate wells and replaced with 2 ml complete medium containing Polybrene (cat. no., sc-134220; Santa Cruz Biotechnology, Inc.) at a final concentration of 5 µg/ml. Cells were transfected with control (scramble, 20 µl) or CD74 shRNA lentiviral particles (20 µl) diluted in media according to the manufacturer's protocol in 48 h.
Downstream tips
Infected cells were selected with puromycin (5 µg/ml; cat. no., 11811-023; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). A total of 72 h after transfection, transfected cells were verified by RT-PCR and western blotting analysis, comparing untreated and scramble cells.

Publication protocol

The CD74 shRNA lentiviral particles (cat. no., sc-35023-V; 1.0×106/200 µl; Santa Cruz Biotechnology, Inc.) targeting the human CD74 transcript and control shRNA lentiviral particles (cat. no., sc-108080; 1.0×106/200 µl; Santa Cruz Biotechnology, Inc.) were used to knock down CD74 in HT-1376 cells. Cells were seeded at 2×105 cells/well in 6-well plates (Corning Incorporated, Corning, NY, USA) and grown to 60% confluence on the day of transfection. The media was removed from the plate wells and replaced with 2 ml complete medium containing Polybrene (cat. no., sc-134220; Santa Cruz Biotechnology, Inc.) at a final concentration of 5 µg/ml. Cells were transfected with control (scramble, 20 µl) or CD74 shRNA lentiviral particles (20 µl) diluted in media according to the manufacturer's protocol in 48 h. Infected cells were selected with puromycin (5 µg/ml; cat. no., 11811-023; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). A total of 72 h after transfection, transfected cells were verified by RT-PCR and western blotting analysis, comparing untreated and scramble cells.

Full paper   Login or join for free to view the full paper.

Reviews

CD74 siRNA and shRNA Plasmids (h) from Santa Cruz Biotechnology has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Discussion

5 years ago

Author: Keith L. Morrison Canada

siRNA/RNAi/miRNA transfection human

I would like to regulate the expression of a gene and in order to do that, I have purchased specific siRNA. After optimizing my transfection protocol and using electroporation I have achieved a 60-70% reduction of the gene of interest. However, I cannot observe a significant reduction of mRNA expression but only a reduction of protein. What might be the problem? Could the problem be in my cell treatment method?

Share your thoughts or question with experts in your field by adding a discussion!

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing siRNA / RNAi /miRNA transfection Human Cells - HT-1376 CD74 using CD74 siRNA and shRNA Plasmids (h) from Santa Cruz Biotechnology.

View full paper   Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from Santa Cruz Biotechnology for CD74 siRNA and shRNA Plasmids (h) below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing siRNA / RNAi /miRNA transfection Human Cells - HT-1376 CD74 using CD74 siRNA and shRNA Plasmids (h) from Santa Cruz Biotechnology. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms